OTTAWA, March 14 /CNW Telbec/ - Health Canada is advising consumers not
to use MIAOZI Slimming Capsules because they have been found to contain
sibutramine, a prescription medication that should only be taken under medical
MIAOZI, manufactured by Bainian Pharmacy Group of Hong Kong, is promoted
as a weight-loss product. The product was tested and found to contain
sibutramine, a prescription medication used to suppress appetite. Canadian
Customs discovered the product at an international mail processing facility.
The green-coloured capsules are packaged in silver and green blister packs.
The use of sibutramine may cause serious side-effects, including
cardiovascular reactions, such as increased blood pressure, chest pain, and
stroke. Sibutramine may interact with a number of other medications. Patients
should be monitored by their physician while they are taking sibutramine.
Sibutramine should not be taken by people who have had a heart attack,
coronary artery disease, heart-related chest pain, irregular heart beats,
congestive heart failure, a stroke or symptoms of a stroke, in individuals
with controlled or poorly controlled high blood pressure, or in patients who
are depressed or have a pyschiatric illness. Sibutramine is not recommended
for women who are pregnant, breastfeeding or planning to become pregnant.
MIAOZI products are not authorized for sale in Canada and have not been
found in the Canadian marketplace. The product is available to Canadians
though the internet. In addition, these products could be purchased by
Canadians travelling abroad or have been brought into Canada through personal
Canadians who have purchased MIAOZI products are advised not to use them,
and should consult with a health care professional if they have concerns about
their health related to the use of the product.
Consumers requiring more information about this advisory can contact
Health Canada's public enquiries line at (613) 957-2991, or toll free at
To date, no adverse reactions from the use of this product have been
reported in Canada. To report a suspected adverse reaction with this or any
other health product, please contact the Canadian Adverse Drug Reaction
Monitoring Program (CADRMP) of Health Canada by one of the following methods:
Marketed Health Products Directorate
Health Protection Building, Tunney's Pasture, AL 0701C
Ottawa, Ontario K1A 0K9
Egalement disponible en français
For further information:
For further information: Media Inquiries: Alastair Sinclair, Health
Canada, (613) 957-1803; Public Inquiries: (613) 957-2991, 1-866 225-0709